Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Thaiss

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Transplantation Proceedings|February 21, 2023
Human Leucocyte Antigen-Matching Can Improve Long Term Outcome of Renal Allografts from Donors Older Than 75 YearsMartina Koch, Daniel Zecher, Kai Lopau, et al.
American Journal of Physiology. Renal Physiology|July 20, 2012
Rho-kinase inhibition prevents proteinuria in immune-complex-mediated antipodocyte nephritisCatherine Meyer-Schwesinger, Silke Dehde, Marlies Sachs, et al.
Journal of the American Society of Nephrology : JASN|November 18, 2015
Inhibitor of NFκB Kinase Subunit 2 Blockade Hinders the Initiation but Aggravates the Progression of Crescentic GNJanine Gotot, Eveline Piotrowski, Martin S Otte, et al.
American Journal of Physiology. Renal Physiology|February 20, 2009
Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-kappaB p65 signalingCatherine Meyer-Schwesinger, Silke Dehde, Claudia von Ruffer, et al.
Kidney International|April 28, 2019
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patientsClaudia Sommerer, Barbara Suwelack, Duska Dragun, et al.
Frontiers in Transplantation|July 12, 2024
Everolimus plus reduced calcineurin inhibitor prevents <i>de novo</i> anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA studyWolfgang Arns, Aurélie Philippe, Vanessa Ditt, et al.
Frontiers in Transplantation|July 12, 2024
Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudyAurélie Philippe, Wolfgang Arns, Vanessa Ditt, et al.
Cellular and Molecular Life Sciences : CMLS|April 19, 2023
IKK1 aggravates ischemia-reperfusion kidney injury by promoting the differentiation of effector T cellsNing Song, Yang Xu, Hans-Joachim Paust, et al.
Transplant Immunology|June 10, 2018
Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantationJun Li, Martina Koch, Kathrin Kramer, et al.
The American Journal of Pathology|April 26, 2011
Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathyCatherine Meyer-Schwesinger, Tobias N Meyer, Henning Sievert, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Transplantation Proceedings|February 21, 2023
Human Leucocyte Antigen-Matching Can Improve Long Term Outcome of Renal Allografts from Donors Older Than 75 YearsMartina Koch, Daniel Zecher, Kai Lopau, et al.
American Journal of Physiology. Renal Physiology|July 20, 2012
Rho-kinase inhibition prevents proteinuria in immune-complex-mediated antipodocyte nephritisCatherine Meyer-Schwesinger, Silke Dehde, Marlies Sachs, et al.
Journal of the American Society of Nephrology : JASN|November 18, 2015
Inhibitor of NFκB Kinase Subunit 2 Blockade Hinders the Initiation but Aggravates the Progression of Crescentic GNJanine Gotot, Eveline Piotrowski, Martin S Otte, et al.
American Journal of Physiology. Renal Physiology|February 20, 2009
Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-kappaB p65 signalingCatherine Meyer-Schwesinger, Silke Dehde, Claudia von Ruffer, et al.
Kidney International|April 28, 2019
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patientsClaudia Sommerer, Barbara Suwelack, Duska Dragun, et al.
Frontiers in Transplantation|July 12, 2024
Everolimus plus reduced calcineurin inhibitor prevents <i>de novo</i> anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA studyWolfgang Arns, Aurélie Philippe, Vanessa Ditt, et al.
Frontiers in Transplantation|July 12, 2024
Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudyAurélie Philippe, Wolfgang Arns, Vanessa Ditt, et al.
Cellular and Molecular Life Sciences : CMLS|April 19, 2023
IKK1 aggravates ischemia-reperfusion kidney injury by promoting the differentiation of effector T cellsNing Song, Yang Xu, Hans-Joachim Paust, et al.
Transplant Immunology|June 10, 2018
Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantationJun Li, Martina Koch, Kathrin Kramer, et al.
The American Journal of Pathology|April 26, 2011
Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathyCatherine Meyer-Schwesinger, Tobias N Meyer, Henning Sievert, et al.
Pageof 6